ZYXI — Zynex, Inc.

Zynex, Inc. Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: $13.4 million, a significant decline from $50 million in Q3 2024.
• Device Revenue: $7.1 million; Supplies Revenue: $6.3 million.
• Gross Profit: $8.1 million (60% of revenue), down from $39.8 million (80% of revenue) in the prior year.
• Net Loss: $42.9 million ($1.42 per share), compared to net income of $2.4 million in Q3 2024.
• Adjusted EBITDA: Loss of $12.3 million, down from a positive $5.1 million in Q3 2024.
• Cash Position: $13.3 million as of September 30, 2025; negative cash flow of $6.3 million for the quarter.
• Convertible Debt: $60 million in convertible senior notes due May 2026; the company entered a 30-day grace period for a $1.5 million interest payment.

2. Strategic Updates and Business Highlights

• New management team focused on compliance and operational improvements, including leadership in sales, legal, compliance, and strategic marketing.
• Implementation of a new resupply order fulfillment policy aimed at enhancing patient engagement and satisfaction.
• Early signs of stabilization in customer order volumes despite a reduced sales force; efforts to improve sales productivity and order conversion are underway.
• Engaged Providence LLC to explore strategic alternatives, including potential capital raising and restructuring strategies.

3. Forward Guidance and Outlook

• The management remains cautiously optimistic about the company's future, emphasizing the quality of the NexWave electrotherapy device and its potential market impact.
• Ongoing discussions with government agencies regarding compliance and potential reinstatement of TRICARE payments are critical for future revenue recovery.
• Continued focus on improving revenue and cash flow performance through operational efficiencies and strategic partnerships.

4. Bad News, Challenges, or Points of Concern

• Revenue decline attributed to TRICARE payment suspension and changes in payer claim review practices, leading to denials and delays.
• Significant net loss and asset impairment charge of $50.7 million during the quarter, primarily affecting goodwill and intangible assets.
• Cash burn remains a concern with the company needing to address its convertible notes maturity and overall liquidity to continue operations.
• The ongoing government investigations pose uncertainty regarding future compliance and operational stability.

5. Notable Q&A Insights

• Management acknowledged the challenges faced in Q3 and emphasized the need for a turnaround strategy.
• Questions regarding the timeline for resolving government investigations and potential TRICARE reinstatement were met with cautious optimism, though no specific timelines were provided.
• Discussions with debt holders regarding restructuring options are ongoing, but outcomes remain uncertain.

Overall, Zynex, Inc. is navigating significant operational challenges while working to stabilize its financial position and improve compliance. The new management team's strategic initiatives aim to address these issues, but the company faces substantial headwinds in the near term.